Business
Collaboration with Medical University of Vienna
Collaboration with Medical University of Vienna.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 8605R Angle PLC 17 September 2014 \n \n\n \n\n\n\n\nFor immediate release\n\n\n 17 September 2014\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nOVARIAN CANCER COLLABORATION WITH THE MEDICAL UNIVERSITY OF VIENNA\n \nANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce it has signed a collaboration agreement with the Ludwig Boltzmann Cluster 'Translational Oncology' located at the Medical University of Vienna to investigate the clinical use of the Parsortix system for ovarian cancer. \n \nThe collaboration is led by the head of the interdisciplinary Molecular Oncology Group at Medical University of Vienna, Professor Robert Zeillinger. \n \nThe Medical University of Vienna is one of the leading research institutions in Europe. Prof Zeillinger has 30 years' experience in the field of molecular oncology, experimental oncology, gynaecologic oncology, and was initiator and coordinator of the EU FP6 project OVCAD (ovarian cancer diagnosing a silent killer). He is author and co-author of more than 200 scientific publications and holds several patents.\n \nThe Molecular Oncology Group is an active member of EUTROC (European Network for Translational Research in Ovarian Cancer), which brings together all the leading ovarian cancer experts in Europe and is leading a number of Phase I and Phase II clinical trials for new drugs to address ovarian cancer. The Group is also a member of TOC (International Tumour Bank Ovarian Cancer Initiative), where Prof Zeillinger serves as a member of the scientific board.\n \nFurthermore, Prof Zeillinger and his team are taking the lead on 'companion diagnostics' in the major GANNET53 Europe-wide multi-centre ovarian cancer clinical trial to test a new drug strategy for chemotherapy resistant ovarian cancer with Phase I and Phase II trials planned for 2015.\n \nProf Zeillinger and his team are evaluating the Parsortix system for its efficacy at capturing circulating tumour cells (CTCs) from ovarian cancer patient blood with the ambition of using the system in combination with RNA markers for CTCs that have already been developed by the team. There is particular interest in the Parsortix system as it is epitope-independent and does not use an antibody-based capture process, which is known to be limited in its...